Therapeutic evaluation of polyamine analogue drug candidates against Enterocytozoon bieneusi in a SCID mouse model.
Enterocytozoon bieneusi is the most common cause of chronic diarrhea in individuals with human immunodeficiency virus infection or AIDS, and there is no effective therapy. The inhibitory activities of polyamine analogues (PG-11157, PG-11158, and PG-11302) against E. bieneusi infection were evaluated in SCID mice preconditioned with anti-gamma interferon monoclonal antibody intraperitoneally (i.p.). Mice were challenged orally with 10(4) E. bieneusi spores, and groups of mice were treated orally or i.p. 14 days later for 7 days. The inhibitory activities of the drugs against infection were determined by enumerating the E. bieneusi spores in feces three times a week by an immunofluorescence assay. Immunohistochemistry staining confirmed the infection within enterocytes. Oral administration of the analogues PG-11157 (at 150 or 75 mg/kg of body weight/day) and PG-11302 (at 250 mg/kg/day) had significant inhibitory activity (96.2 to 99.6%) that was slightly better than that of fumagillin (1 mg/kg/day; 93.7%). The inhibitory activity with i.p. injection was significant only with PG-11302 at 20 mg/kg/day. While the treatments considerably reduced the levels of spore excretion, neither polyamine analogues nor fumagillin was able to completely eliminate E. bieneusi, as excretion reappeared within 7 days after the end of treatment. Drug toxicity was apparent during treatment, but it disappeared at the end of treatment. These results warrant further examination of the analogues PG-11157 and PG-11302.
Feng
Xiaochuan
X
Division of Infectious Diseases, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
Reddy
Venudhar K
VK
Mayanja-Kizza
Harriet
H
Weiss
Louis M
LM
Marton
Laurence J
LJ
Tzipori
Saul
S
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use; D004195:Disease Models, Animal; D021862:Enterocytozoon / Q000187:drug effects*; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use; D051379:Mice; D016513:Mice, SCID; D016881:Microsporidiosis / Q000188:drug therapy*; D011073:Polyamines / Q000494:pharmacology / Q000627:therapeutic use*; D012717:Sesquiterpenes / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects
D000935:Antifungal Agents; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D011073:Polyamines; D012717:Sesquiterpenes; C026211:fumagillin